Prasco Laboratories, a privately held healthcare company located in Mason, Ohio, has began shipping of the authorised generic of Ferring’s Lysteda (tranexamic acid) tablets in 650 mg strength in the US under the Prasco label. Tranexamic acid tablets are AB-rated and substitutable for the brand Lysteda tablets.

“We are pleased to welcome Ferring Pharmaceuticals into Prasco’s family of brand partners with the introduction of the Authorised Generic of Lysteda tablets,” stated Chris Arington, Prasco's chief executive officer. “With the choice of tranexamic acid tablets, customers benefit from the same consistent supply and quality of the brand they are accustomed to," Arington continued.

Tranexamic acid tablets 650 mg is an antifibrinolytic drug indicated for the treatment of cyclic heavy menstrual bleeding. The most common adverse reactions in clinical trials (=5%, and more frequent in Lysteda subjects compared to placebo subjects) were: headache, sinus and nasal symptoms, back pain, abdominal pain, musculoskeletal pain, joint pain, muscle cramps, migraine, anemia, and fatigue.

Lysteda is contraindicated in women with active thromboembolic disease or a history or intrinsic risk of thrombosis or thromboembolism, including retinal vein or artery occlusion; or known hypersensitivity to tranexamic acid. The risk of thrombotic and thromboembolic events may increase further when hormonal contraceptives are administered with Lysteda, especially in women who are obese or smoke cigarettes. Women using hormonal contraception should use Lysteda only if there is a strong medical need and the benefit of treatment will outweigh the potential increased risk of a thrombotic event. Do not use Lysteda in women who are taking more than the approved dose of a hormonal contraceptive.

Ferring Pharmaceuticals Inc. is a research-driven, specialty  biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology.